-

AM Best Affirms Credit Ratings and Assigns National Scale Rating to Egyptian Takaful Property & Liability Insurance Company (Egyptian Joint Stock Company)

LONDON--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of B- (Fair) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “bb-” (Fair) of Egyptian Takaful Property & Liability Insurance Company (Egyptian Joint Stock Company) (EGTAK) (Egypt). The outlook of these Credit Ratings (ratings) is stable. Additionally, AM Best has assigned the Egypt National Scale Rating (NSR) of aa+.EG (Superior) to EGTAK with a stable outlook.

The ratings reflect EGTAK’s balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and marginal enterprise risk management. The company’s FSR and Long-Term ICR were assigned on 29 July 2024 (see related press release).

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2024 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Stanislav Stoev, ACCA, CFA
Senior Financial Analyst
+44 20 7397 0306
stanislav.stoev@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

AM Best


Release Versions

Contacts

Stanislav Stoev, ACCA, CFA
Senior Financial Analyst
+44 20 7397 0306
stanislav.stoev@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

More News From AM Best

AM Best Assigns Credit Ratings to Charp Re, Ltd.

MEXICO CITY--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb” (Good) to Charp Re, Ltd. (Charp Re) (Turks & Caicos Islands). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Charp Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management (ER...

AM Best Revises Outlooks to Positive for FMH Insurance Group’s Members

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Farmers Mutual Hail Insurance Company of Iowa and its reinsured affiliate, FMH Ag Risk Insurance Company. Both companies are domiciled in West Des Moines, IA and are collectively referred to as FMH Insurance Group (FMH).The Credit Ratings (ratings) reflect FMH’s overall balance sheet str...

Best’s Commentary: Health Insurers Evaluating Balance Between Pharmacy Costs and Long-Term Value of GLP-1 Therapies

OLDWICK, N.J.--(BUSINESS WIRE)--As pharmacy cost trends continue to rise and clinical evidence evolves, health insurers face a fundamental question on whether improvements in long-term morbidity and the potential for improved mortality outcomes ultimately justify significant investments in GLP-1 therapies, according to a new AM Best commentary. The Best’s Commentary, “GLP-1 Therapies: Evaluating the Balance Between Pharmacy Costs and Long-Term Value,” states that GLP-1 therapies have become one...
Back to Newsroom